Head-To-Head Survey: GN Store Nord (OTCMKTS:GNNDY) versus RxSight (NASDAQ:RXST)

RxSight (NASDAQ:RXST) and GN Store Nord (OTCMKTS:GNNDY) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares RxSight and GN Store Nord’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
GN Store Nord	-4.32%	-2.44%	-0.88%

Valuation & Earnings

This table compares RxSight and GN Store Nord”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48 million	1.44	-$38.94 million	($1.13)	-4.12
GN Store Nord	$2.54 billion	0.96	$98.86 million	($1.80)	-27.02

GN Store Nord has higher revenue and earnings than RxSight. GN Store Nord is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

78.8% of RxSight shares are owned by institutional investors. 10.1% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for RxSight and GN Store Nord, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3	7	2	0	1.92
GN Store Nord	0	3	2	0	2.40

RxSight currently has a consensus price target of $8.17, indicating a potential upside of 75.75%. Given RxSight’s higher probable upside, equities research analysts clearly believe RxSight is more favorable than GN Store Nord.

Volatility and Risk

RxSight has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, GN Store Nord has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500.

Summary

GN Store Nord beats RxSight on 7 of the 13 factors compared between the two stocks.

About RxSight

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

About GN Store Nord

GN Store Nord A/S provides hearing, audio, video, and gaming solutions in Denmark, rest of Europe, North America, and internationally. The company operates through GN Hearing and GN Audio segments. The GN Hearing segment produces and sells hearing instruments and products. The GN Audio segment supplies headsets, video cameras, and speakerphones for professional use and consumer products. It offers its products under the ReSound, Jabra, Beltone, Interton, Danavox, BlueParrott, FalCom, and SteelSeries brands. GN Store Nord A/S was founded in 1869 and is based in Ballerup, Denmark.